Technical Analysis for ACHL - Achilles Therapeutics plc

Grade Last Price % Change Price Change
C 1.10 0.00% 0.00
ACHL closed unchanged on Monday, March 18, 2024, on 41 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Support Bullish 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion -0.90%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 14 hours ago
Down 2 % about 15 hours ago
Down 1% about 15 hours ago
Up 3% about 16 hours ago
Up 2% about 16 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Cancer Treatment Cancer Immunotherapy Antineoplastic Drugs Melanoma Orphan Drug Breakthrough Therapy Bladder Cancer Head And Neck Cancer Renal Cell Carcinoma Advanced Non Small Cell Lung Cancer Head And Neck Squamous Cell Carcinoma Triple Negative Breast Cancer Immuno Oncology Biopharmaceutical

Is ACHL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.76
52 Week Low 0.7402
Average Volume 872,192
200-Day Moving Average 0.95
50-Day Moving Average 1.07
20-Day Moving Average 1.28
10-Day Moving Average 1.20
Average True Range 0.12
RSI (14) 43.82
ADX 41.05
+DI 19.62
-DI 15.40
Chandelier Exit (Long, 3 ATRs) 1.40
Chandelier Exit (Short, 3 ATRs) 1.30
Upper Bollinger Bands 1.54
Lower Bollinger Band 1.02
Percent B (%b) 0.16
BandWidth 41.25
MACD Line 0.02
MACD Signal Line 0.06
MACD Histogram -0.0407
Fundamentals Value
Market Cap 44.86 Million
Num Shares 40.8 Million
EPS -1.90
Price-to-Earnings (P/E) Ratio -0.58
Price-to-Sales 0.00
Price-to-Book 0.25
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.21
Resistance 3 (R3) 1.21 1.17 1.19
Resistance 2 (R2) 1.17 1.15 1.17 1.18
Resistance 1 (R1) 1.14 1.13 1.12 1.14 1.18
Pivot Point 1.10 1.10 1.10 1.10 1.10
Support 1 (S1) 1.07 1.08 1.05 1.07 1.02
Support 2 (S2) 1.03 1.06 1.03 1.02
Support 3 (S3) 1.00 1.03 1.01
Support 4 (S4) 1.00